PCOS, or polycystic ovary syndrome, is getting a new title, and it’s a mouthful. As announced by a May 2026 article in prestigious medical journal The Lancet, PCOS is being renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS. Following a three-year transition period, the term ‘PCOS’ will be permanently replaced with ‘PMOS’ in international medical research, doctor’s offices, education, and advocacy efforts.
Here’s why the name change isn’t just a rebrand or glow-up, but a worthwhile, needed acknowledgment that ovarian cysts aren’t the main focus of this long-underdiagnosed condition that affects 170 million worldwide.
How our understanding of PCOS has evolved in recent years
Historically, PCOS was considered to be a reproductive problem driven by excess androgens (sex hormones that trigger male characteristics). Internally, women with PCOS were believed to have multiple cysts on the ovaries, hence the ‘polycystic’ in the name. External characteristics included irregular cycles, anovulation (no ovulation), hair in places it didn’t belong and more consistent with male hair growth patterns (think on the chin or neck and chest) and being overweight or obese.
In recent years, we’ve chronicled multiple shifts in our cultural and medical understanding of PCOS. We’ve known for some time that PCOS doesn’t look the same for everyone, as we noted with our article on “lean PCOS.” What’s more, it has health implications for other body systems beyond the reproductive system, as we covered in our articles on PCOS and memory loss in mid-life and PCOS and hearing loss. We also spotlighted the increasingly clear connection between PCOS and metabolic issues like insulin resistance.
The new name, Polyendocrine Metabolic Ovarian Syndrome (PMOS), ties all the above threads together, and was developed from the results of 22,000 survey responses from patients and healthcare professionals, plus the collaboration of dozens of domestic and international medical and advocacy organizations, among them: The International PCOS Network – Monash University, NHMRC Centre for Research Excellence in Women’s Health in Reproductive Life (CRE-WHiRL), AE-PCOS (International Androgen Excess and Polycystic Ovary Syndrome Society), and UK patient group Verity).
What the name change signifies
The name change reflects three key facts. First, ovarian cysts aren’t a main feature of PCOS/PMOS. Second, PMOS is a chronic condition, not just affecting reproductive-aged women. Thirdly, PMOS isn’t just a reproductive issue.
The name change reflects three key facts. First, ovarian cysts aren’t a main feature of PCOS/PMOS. Second, PMOS is a chronic condition, not just affecting reproductive-aged women. Thirdly, PMOS isn’t just a reproductive issue.
Ovarian cysts aren’t a main feature of PCOS/PMOS
“What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated,” stated Professor Helena Teede, the Monash University professor who spearheaded the name change, according to a press release from the Endocrine Society.
What was previously believed to be multiple cysts on the ovaries is actually a case of arrested development: clusters of immature follicles that never reached the point of ovulation and look like cysts on imaging.
PMOS is a chronic condition…
The name change also acknowledges that PCOS doesn’t strictly affect reproductive-aged women, as we alluded to in our article on the connection between PCOS and cognitive decline later in life, nor does it simply go away over time. As one example, the metabolic impacts of PCOS don’t just end when a woman’s periods stop.
…And it might not be just for women
And here’s the kicker, PMOS may not be a strictly female issue either. Back in September of 2025, Slate published an article noting that certain PCOS-associated genes in affected women were also noted in their first-degree male relatives. Unlike their female counterparts, these men tended to have too-low levels of androgens. Furthermore, they didn’t have reproductive issues so much as skin-related (early male-pattern baldness) and metabolic ones, like insulin resistance and obesity.
An April 2026 Stat article clarified, “At present, this condition is diagnosed as PCOS in women; in men, similar features, especially in relatives, reflect shared genetic and metabolic pathways rather than a formally defined syndrome,” quoting Okan Bülent Yıldız, a Turkish professor of medicine and endocrinology. Yıldız co-authored a widely-cited April 2025 article in Nature exploring how metabolic dysfunction runs in whole families of women with PCOS, and arguing that metabolic issues, not just reproductive problems, are key characteristics of PCOS.
PMOS is a metabolic, hormonal, mental health, skin, and reproductive condition
The Lancet article spelled out the potential manifestations of PMOS from the perspective of multiple body systems. Symptoms might be “metabolic (ie, obesity, dysglycaemia, type 2 diabetes, hypertension, dyslipidaemia, metabolic dysfunction-associated steatotic liver disease, cardiovascular disease, and sleep apnoea), reproductive (ovulatory disturbances, irregular menstrual cycles, infertility, pregnancy complications, and endometrial cancer), psychological (depression, anxiety, poor quality of life, and eating disorders), and dermatological (acne, alopecia, and hirsutism).”
Symptoms of PMOS might be “metabolic, reproductive, psychological, and dermatological.”
The title ‘Polyendocrine Metabolic Ovarian Syndrome’ represents the multisystem hormonal, metabolic, and reproductive effects of this condition.
RRM experts and women’s health advocates are thrilled with the name change
Social media was already abuzz on May 12, with women’s health advocates and restorative reproductive medicine practitioners celebrating the news.
The Endometriosis Foundation of America recognized that many women with endometriosis also experience PCOS and stand to gain from the name change.
An OB/GYN and reproductive endocrinologist’s take
Popular double board-certified OB/GYN and reproductive endocrinologist Dr. Natalie Crawford, MD wrote, in part, “…importantly, many patients and advocacy groups pushed for this change because the current name has contributed to years of confusion, delayed diagnosis, and dismissal. A new name won’t fix everything. But it may help move the conversation toward earlier diagnosis, better research, and more comprehensive care.”
An OB/GYN and NaPro-trained surgeon’s take
Napro-trained OB/GYN Dr. Naomi Whittaker reshared a post from the account Sacred as a Mother, which read, in part, “Polyendocrine Metabolic Ovarian Syndrome has never been a condition of the ovary. But a larger metabolic event using the ovary to communicate. The cystic follicles, insulin resistance, and cyclic dysregulation were delegates for a female living system stuck in an evolutionary mismatch with modern biological antagonism. The ovaries have been downstream the entire time. Wise organs communicating with us, showing us the fire–and we blamed the smoke.”
Whittaker commented, “I’m obsessed with this analysis and update. 🔥🔥🔥🔥🔥🔥 every thing. The female organs have been the scapegoats the entire time! ENOUGH with the misogyny!!”
A functional nutritionist’s take
Ginny Noce of The Women’s Health RN called the name change “a step in the right direction” while cautioning against focusing solely on the metabolic aspects of PMOS. She wrote, “There are seven critical drivers in addition to insulin resistance that I address in every PCOS/PMOS case in my practice.” Among them are inflammation, oxidative stress, gut health, nutrient deficiencies. In her post, Noce also questioned whether overemphasizing the metabolic dysfunction part of PCOS/PMOS could “potentially just lead to more Metformin and GLP-1s?” She summed up, “Women with PCOS/PMOS deserve a full-scope investigation and care plan—not just a new drug target.”
The bottom line on the PCOS rebrand
The name change from PCOS to PMOS isn’t some slick marketing tactic (after all, ‘polyendocrine metabolic ovarian syndrome’ doesn’t really roll off the tongue). It’s the result of years of thoughtful collaboration between healthcare professionals and thousands of women’s lived experience. PCOS, now PMOS, isn’t ultimately about ovarian cysts, nor is it a strictly reproductive issue.
While not tacitly acknowledged by most mainstream commentaries, the quiet star of the show here is the menstrual cycle as a fifth vital sign of whole body women’s health. As the Sacred as a Mother account observed, the ovaries are “Wise organs communicating with us, showing us the fire–and we blamed the smoke.” Menstrual cycle charting, a vital component of fertility awareness methods and natural family planning, helps identify cycle irregularities and issues that can help point to PCOS/PMOS for diagnosis and treatment.
The quiet star of the show here is the menstrual cycle as a fifth vital sign of whole body women’s health. As the Sacred as a Mother account observed, the ovaries are “Wise organs communicating with us, showing us the fire–and we blamed the smoke.”
Here’s to a new name, new hope, and better care for millions of women the world over.
